Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of enpatoran in adults with active cutaneous manifestations of lupus erythematosus, with or without systemic disease, in this global, multicenter Phase 3 study. The study aims to assess enpatorans effect over 24 weeks compared to a placebo, focusing on skin disease activity and safety outcomes. Participants include those diagnosed with discoid, subacute cutaneous lupus, or active acute cutaneous lupus alongside systemic lupus erythematosus. Participants will receive either enpatoran tablets or matching placebo tablets orally twice daily for 24 weeks Day 1 to Day 168, alongside investigator-recommended standard of care. The study includes scheduled visits every 4 weeks, with a telehealth visit at Week 2. The intervention is administered as film-coated tablets, and the treatment period lasts for 24 weeks within an overall study duration of up to 35 weeks. During the study, participants will be monitored through regular visits every 4 weeks to assess skin disease using the Cutaneous Lupus Erythematosus Disease Area and Severity Index CLASI and other clinical measurements. Researchers will evaluate skin improvement, lupus disease activity, adverse events, laboratory parameters, and corticosteroid use. Safety and treatment effects will be closely followed during and after the treatment period, with the primary outcome assessed at Week 24.
Actively Recruiting
Researchers are evaluating the safety and activity of barzolvolimab compared to a placebo in adults with cold induced urticaria ColdU or symptomatic dermographism SD who continue to have symptoms despite using H1-antihistamines. This Phase 3, randomized, double-blind, placebo-controlled study aims to better understand treatment options for these chronic skin conditions. Participants will first undergo a screening period lasting up to 4 weeks. Following this, there is a 24-week treatment phase where participants receive either barzolvolimab or a placebo. Those receiving barzolvolimab get a 450mg injection at the start, then 150mg every 4 weeks. After this, all participants receive 300mg barzolvolimab every 8 weeks for 28 weeks. Finally, there is a 16-week follow-up period where participants are observed without treatment. During the study, participants will complete daily symptom diaries and attend regular visits for assessments. Researchers will measure responses to provocation testing at various time points, clinical symptoms like itch and hives, and changes in temperature and friction thresholds. Quality of life related to dermatology will also be evaluated. Safety and tolerability are monitored throughout the study, which lasts over a year from screening to follow-up.
Actively Recruiting
Researchers are evaluating whether tralokinumab given as subcutaneous injections along with topical corticosteroids TCS is safe and effective for treating moderate-to-severe atopic dermatitis AD in children and infants. The trial involves two age groups children aged 2 to under 12 years and infants aged 6 months to under 2 years. Children are randomized to receive either tralokinumab plus TCS or placebo plus TCS, while infants receive open-label tralokinumab plus TCS. This Phase 3 trial will last up to four years with visits every two weeks during the first year and every six weeks thereafter, including some phone visits.
Actively Recruiting
Researchers are investigating the real-world use of encorafenib plus binimetinib for patients with unresectable advanced or metastatic melanoma that has a BRAF V600 mutation. This observational study focuses on documenting treatment effects, quality of life, safety, and tolerability after these drugs became commercially available in Germany, Austria, and Switzerland. The study specifically looks at patients treated in the first and second line settings after prior checkpoint inhibitor therapy. The study observes patients who are treated with encorafenib plus binimetinib according to the approved product guidelines. Participants may have started this treatment up to six months before joining the study or may begin treatment soon after enrollment. The study tracks treatment details, effectiveness, side effects, and patient-reported outcomes over a median treatment duration of about 12 months, with a total observation period of up to 90 months. Participants will be followed through regular documentation of their disease and treatment progress, including patient and disease profiles, treatment sequences, adverse events, and quality of life assessments using questionnaires. The main outcome measured is progression-free survival at 12 months after treatment start. Researchers will also evaluate treatment duration, interruptions, dose intensity, and physician satisfaction. Long-term safety and prognostic factors will be monitored throughout the observation period until study completion in September 2027.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and anti-tumor activity of a new drug called IMA402 in adults with recurrent or refractory solid tumors. This clinical trial is designed in multiple phases to find the right dose of IMA402 alone and combined with other treatments like pembrolizumab, a checkpoint inhibitor. The study aims to better understand how well IMA402 works and its effects in patients whose cancer has returned or not responded to previous treatments. The trial includes three parts Phase Ia focuses on finding the best dose by increasing or decreasing amounts of IMA402 alone or with a checkpoint inhibitor. Phase Ib extends dosing based on these results, and Phase II studies selected patient groups receiving IMA402 alone or combined with other therapies at recommended doses. Treatments involve intravenous infusions of IMA402, either alone or combined with checkpoint inhibitors, chemotherapy, monoclonal antibodies, or another investigational drug, IMA401. Participants will undergo regular assessments including safety checks, monitoring side effects, and measuring tumor response using criteria like RECIST 1.1. Researchers will collect data on adverse events, dose adjustments, and overall treatment effects over several months. The study also observes how IMA402 behaves in the body. Participants can expect ongoing evaluations throughout treatment and follow-up periods lasting up to around 40 months to understand the drugs activity and safety profile in these cancer patients.
Actively Recruiting
Researchers are studying the long-term safety and effectiveness of pembrolizumab MK-3475 in participants with advanced tumors or blood cancers who were part of previous pembrolizumab-based studies. This extension study includes participants currently receiving treatment or in follow-up from parent trials. It consists of three phases the First Course Phase, Survival Follow-up Phase, and Second Course Phase, depending on the participants status at the end of their previous study. Participants may receive pembrolizumab alone or combined with standard of care treatments, lenvatinib, or other study drugs like olaparib and MK-4280, delivered mainly by intravenous infusion or oral capsules. Dosing schedules vary, including pembrolizumab administered every 3 or 6 weeks for up to 35 or 17 doses depending on the phase. Some participants may take lenvatinib orally daily, timed with pembrolizumab infusions, while others may receive investigational combination therapies or standard care treatments according to their parent studys protocol. During the study, participants will have regular infusions or oral dosing and be monitored over several years for overall survival and other outcomes like progression-free survival and adverse events. Researchers will assess safety and efficacy for up to approximately 10 years, with detailed tracking of side effects and treatment discontinuations. Study visits and assessments will be conducted to evaluate organ function, disease status, and any treatment-related effects throughout the study duration.
Actively Recruiting
Long-Term Safety Study of Nivolumab and Other Cancer Therapies in Patients from BMS-Sponsored Trials
Researchers are examining the long-term safety of nivolumab monotherapy and its combinations with other cancer therapies across various tumor types. This phase 2 study focuses on patients who have previously participated in Bristol-Myers Squibb-sponsored trials involving nivolumab and other cancer treatments. The goal is to monitor safety outcomes over an extended period while patients continue or resume treatment. Participants receive specified doses of nivolumab alone or in combination with other drugs such as ipilimumab, cabozantinib, trametinib, relatlimab, capecitabine, bevacizumab, temozolomide, and others according to their assigned study group. The study includes multiple experimental arms with different drug combinations and dosing schedules, all delivered as drug treatments. Participants continue treatment based on eligibility from their parent studies, including those who are on treatment hold or eligible for rechallenge. Throughout the study, participants undergo regular safety assessments to monitor adverse events, serious adverse events, immune-mediated effects, and any events leading to treatment discontinuation. Monitoring begins from the first day of treatment and continues up to 135 days after treatment ends. Researchers also track incidences of death during this period. The total participation duration spans from enrollment through ongoing treatment and post-treatment safety follow-up, with data collected to evaluate long-term treatment safety.
Actively Recruiting
Researchers are investigating why bee venom immunotherapy VIT is less effective than vespid VIT for patients with bee venom allergy. The study focuses on whether predominant sensitization to specific bee venom allergens, especially Api m 10, increases the risk of treatment failure. This multicenter observational study aims to clarify these risk factors to improve future bee venom treatments. Participants will receive bee venom immunotherapy following protocols chosen by the patients. Before treatment, blood samples will be collected to measure specific immunoglobulin E levels for different bee venom components. After reaching the maintenance dose, participants will undergo a sting challenge, and the outcomes will be recorded to assess treatment success or failure. Throughout the study, researchers will evaluate factors such as sensitization to various bee venom allergens, immunoglobulin G4 levels after treatment, systemic side effects, and use of antihypertensive medications. The main outcome is to determine if predominant Api m 10 sensitization is linked to treatment failure within about six months after the sting challenge. Participant involvement includes blood sampling and clinical assessments, with the total study period lasting until March 2029.
Actively Recruiting
Researchers are evaluating the real-world use of nemolizumab for treating moderate-to-severe atopic dermatitis AD in adolescents and adults. This observational study aims to assess the treatments effectiveness through physician evaluations and patient-reported outcomes over six months, providing insight into how the medication performs in everyday clinical practice. Participants receiving nemolizumab as part of their routine care will be observed for about 12 months. Treatment decisions are made by the participants physician before joining the study, with no extra visits or tests beyond usual medical care. A sub-study in Germany and the UK involves daily remote reporting of symptoms such as peak and average itch, sleep disturbance, and pain for the first two weeks. During the study, participants will have regular medical visits as determined by their doctors, with data collected from routine assessments and patient questionnaires. Researchers will measure outcomes like the Investigator Global Assessment and Peak Pruritus Numerical Rating Scale at six months, along with other severity and symptom scores up to 12 months. No additional procedures outside standard care are required, allowing for natural monitoring of treatment effects and safety.
Actively Recruiting
This research is a rollover study for participants who have previously taken part in specific Incyte-sponsored clinical trials involving the drug povorcitinib, aimed at treating Hidradenitis Suppurativa HS. The purpose is to continue evaluating the treatments safety and tolerability over an extended period, building on prior studies. Participants must have completed treatment in the original trials without major safety concerns and shown clinical benefits. Participants will continue to receive povorcitinib orally, following the same dosing schedule and options as in their original parent study. This ongoing treatment phase allows researchers to monitor long-term effects and gather extended safety data. The study is designed as a single-group phase 3b trial focused on treatment. Throughout the study, participants will be regularly monitored for treatment-emergent adverse events over approximately three years. Researchers will also assess specific clinical measures at each visit to evaluate treatment impact. Participants are expected to comply with study procedures, including avoiding pregnancy or fathering children as outlined. The total participation duration extends up to about three years, with regular visits to track safety and treatment outcomes.
1-10 of 11
1